Tele Group Corp. (TMLL): Filings out today!!!!!!!!!

Play Episode

4min

Proactive - Interviews for investors

Tonix Pharmaceuticals launches :TONIX ONE™ A digital breakthrough in migraine management

Tonix Pharmaceuticals is making waves in the healthcare industry with the launch of TONIX ONE™ a fully integrated digital platform designed to empower migraine patients with better tools for understanding and managing their condition. In an exclusive discussion with Proactive’s Steve Darling, Dr. Seth Lederman, CEO of Tonix Pharmaceuticals, unveiled the platform’s innovative features and strategic partnerships aimed at transforming migraine care. By collaborating with UpScript Telemedicine, ProModRx, Blink Health, and a leading mobile application specializing in disease tracking, symptom reporting, and management, TONIX ONE offers a comprehensive, patient-centric solution. Dr. Lederman highlighted that TONIX ONE™ beyond conventional migraine education by providing critical insights into the limitations of oral medications, which can sometimes result in delayed or ineffective symptom relief. The platform bridges the gap between patients and healthcare providers, offering direct access to migraine specialists via telehealth consultations and seamless e-prescription requests—ensuring a faster, more effective pathway to treatment. With this initiative, Tonix Pharmaceuticals aims to not only educate and empower patients in their treatment journey but also eliminate the barriers to care that many migraine sufferers face. By integrating advanced digital health solutions,TONIX ONE™ stands at the forefront of a new era in migraine management, offering patients greater control over their health and well-being. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #Biotech #MigraineTreatment #TonixOne #DigitalHealth #Telemedicine #ZembraceSymTouch #Tosymra #HealthcareInnovation #PharmaNews #ProactiveInvestors

Proactive - Interviews for investors

NanoViricides highlights broad-spectrum antiviral strategy and progress with lead drug candidate

NanoViricides Chief Financial Officer Meeta Vyas joined Steve Darling from Proactive to share updates on the company’s development of broad-spectrum antiviral therapeutics and its unique positioning amid global market uncertainty. Vyas emphasized that NanoViricides, headquartered in Shelton, Connecticut, conducts all of its research and development in-house, which insulates the company from international tariff fluctuations and supply chain disruptions. At the center of the company’s pipeline is NV-387, a broad-spectrum antiviral drug that differs from vaccines in both function and strategy. Rather than targeting specific viral strains, NV-387 works by mimicking the receptor sites used by over 90% of pathogenic viruses—including influenza, RSV, COVID-19, and smallpox. Vyas explained that this approach helps circumvent the problem of viral mutation, which often renders traditional vaccines less effective. “Regardless of how they mutate, they land on the same receptor site. So we copy the receptor site, which is invariant to mutation,” she said, underscoring the robustness of the NanoViricides platform. She also highlighted supportive regulatory developments in the U.S., noting that the new HHS administration has endorsed a more integrated approach to pandemic preparedness, which includes therapeutics like NV-387 as a key component. In light of recent USDA funding initiatives aimed at combating H5N1 avian flu, Vyas said the company is keen to explore applications of NV-387 in that space as well. Currently, NanoViricides is conducting a Phase 2 clinical trial targeting smallpox, following successful Phase 1 results with no reported adverse effects. #proactiveinvestors #nanoviricidesinc #nyseamerican #nnvc NV387 #BroadSpectrumAntiviral #BiotechStocks #AntiviralTherapeutics #SmallpoxTreatment #BirdFlu #RSV #COVID19Treatment #ProactiveInvestors #PharmaInnovation #MeetaVyas #HHS #PandemicPreparedness

Proactive - Interviews for investors

ATOME signs milestone EPC deal with Casale for Villeta project

ATOME PLC (AIM:ATOM) CEO Olivier Mussat talked with Proactive about a landmark milestone for the company’s Villeta green fertiliser project in Paraguay. The company has signed its first definitive engineering, procurement and construction (EPC) agreement with Swiss firm Casale S.A. Mussat explained that this agreement marks the world’s first large-scale green hydrogen fertiliser project to reach the EPC stage, underlining its global relevance. “It’s significant for us as a company because we’ve announced that we had been working on the front-end engineering and design for more than two years now,” Mussat said, noting the long-term collaboration with Casale. He highlighted Casale’s industry-leading expertise, describing the firm as the oldest ammonia licensor globally, with the ability to deliver complex, full-chain fertiliser projects. According to Mussat, the partnership serves as a strategic blueprint for Casale’s future growth. Looking ahead, ATOME aims to reach a final investment decision on the Villeta project by the end of the first half of the year. The company is working to finalise offtake agreements and complete financial documentation for both debt and equity funding. This includes a $115 million equity commitment from Hy24, with further syndication in progress. For more updates on green hydrogen and clean energy developments, visit Proactive’s YouTube channel. Like this video, subscribe, and turn on notifications to stay informed. #ATOMEPLC #GreenHydrogen #EPCContract #FertilizerProject #Casale #SustainableEnergy #CleanTech #HydrogenEconomy #ParaguayProjects #Yara #Hy24

Proactive - Interviews for investors

Novo Resources targets gold at Tibooburra

Novo Resources Corp executive co-chair Mike Spreadborough and exploration manager Kas De Luca talked with Proactive about the company’s current exploration, strategy and key drilling campaigns underway in 2025. Spreadborough detailed the company's focus on standalone projects with the potential to exceed one million ounces, with current efforts centred on drilling programs at the Balla Balla project, Tibooburra Gold Project, and upcoming activity at the John Bull Project. “We’re not chasing brownfields mill feed for an existing processing plant. We’re looking for something new and exciting,” he said. De Luca shared insights into the Clone prospect at Tibooburra, highlighting its strong geological context and mineralisation indicators. “The clone thrust has been really identified and pinpointed now as a foot wall shear zone… that seems to us both in the drilling and in service to carry most of the mineralisation,” she noted. De Luca said results from surface sampling returned grades up to 89 grams per tonne, and the company has only tested a small fraction of a 60km mineralised trend. Novo expects results from three programs between now and July and continues to assess additional farm-in opportunities as part of its strategy. For more videos from Proactive, give this video a like, subscribe to our channel, and turn on notifications so you never miss an update. #GoldExploration #NovoResources #TibooburraGold #GreenfieldsExploration #JuniorMining #RCDrilling #GoldStocks #AustralianMining #MiningUpdates #ProactiveInvestors

Followers	76
Posts	19323
Boards Moderated	2
Alias Born	04/16/2019

Volume:	-
Day Range:
Bid:	1.00
Ask:	1.00
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

TMLL Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free